Q-omics provides the consensus-scored C4B profile across patient tissues and cancer cell-line models. C4B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, C4B is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, C4B protein abundance shows 21,142 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, KIRC, and PDAC as cancer lineages where C4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C4B survival associations across molecular data types. C4B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C4B RNA expression–survival associations across cancer types. High C4B expression shows unfavorable associations in UVM and LGG, but favorable associations in SKCM, MESO, HNSC and KIRC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for C4B RNA expression.
This table summarizes C4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for C4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C4B shows lower tumor expression in BLCA, KICH, LUSC and LUAD and higher tumor expression in KIRC and BRCA. The KIRC box plot shows higher C4B RNA expression in tumor versus normal tissue (log2 FC = +2.459, t-test p < 0.001).
This table shows molecular features associated with C4B in patient tissues and cancer cell lines. In patient samples, C4B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, C4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and STOMACH.
